Fact CheckerSign in

NCT07046299Not yet recruiting

Basilar Artery Occlusion Chinese Endovascular Trial in Patients With Large Core Infarct

Safety and Efficacy of Endovascular Therapy for Acute Basilar Artery Occlusion With Large Core Infarct: A Prospective, Multicenter, Randomized, Open-Label Controlled Trial

Source: ClinicalTrials.gov · Last updated 1 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This study evaluates the safety and efficacy of endovascular therapy for acute basilar artery occlusion with large core infarcts in a multicenter randomized trial.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
314 (estimated)
First submitted
18 Jun 2025
Start date
1 Jul 2025
Primary completion date
29 Feb 2028
Lead sponsor
Capital Medical University
Diseases
Stroke
NCT number
NCT07046299

What you commit to

  • Study type: Interventional
  • Planned participants: 314
  • From 1 Jul 2025 to the primary completion date, 29 Feb 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients in whom baseline NIHSS can not be obtained by a neurologist or emergency physician prior to sedation or intubation.
  • Subject participating in a study involving an investigational drug or device that would impact this study.

Other illness

  • Severe, sustained hypertension (SBP \> 220 mm Hg or DBP \> 110 mm Hg) NOTE: If the blood pressure can be successfully reduced and maintained below these levels using commonly used medications in China for these purposes (including iv antihypertensive drips), the patient can be enrolled.
  • Seizures at stroke onset which would preclude obtaining a baseline NIHSS.
  • Serious, advanced, or terminal illness with anticipated life expectancy of less than one year.
  • History of life threatening allergy (more than rash) to contrast medium.
  • Patients with acute stroke within the first 48 hours after percutaneous cardiac, cerebrovascular interventions and major surgery .
  • Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations.
  • CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).

Lab values

  • Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR \> 3.0.
  • Baseline platelet count \< 50000/µL.
  • Baseline blood glucose of \< 50mg/dL or \>400mg/dL.
  • Renal insufficiency with creatinine ≥ 3 mg/dL.

Other

  • Clinical exclusion criteria:
  • Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.
  • Known diagnosis or clinical suspicion of cerebral vasculitis.
  • Unlikely to be available for 90 days follow-up (e.g. no fixed home address, visitor from overseas).
    • Neuroimaging exclusion criteria:
  • Pons-midbrain-index of ≥ 4 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.
  • Complete cerebellar infarct on CT or MRI with significant mass effect and compression of the fourth ventricle.
  • Complete bilateral thalamic infarction on CT or MRI.
  • Evidence of vertebral occlusion, high grade stenosis or arterial dissection in the extracranial or intracranial segment that cannot be treated or will prevent access to the intracranial clot or excessive tortuosity of cervical vessels precluding device delivery/deployment.
  • Subjects with occlusions in both anterior and posterior circulation.
  • Evidence of intracranial tumor (except small meningioma).

Who the study is looking for

  • Posterior circulation acute ischemic stroke within 24 hours from symptom onset/last seen well.
  • Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA/MRA/DSA.
  • Patients with large core infarction in the posterior circulation, defined as a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) score of 3-5 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.
  • Age ≥18 and ≤80 years.
  • Baseline NIHSS score ≥6 at the time of randomization.
  • No significant pre-stroke functional disability (modified Rankin Scale, mRS ≤ 1).
  • Informed consent obtained from patient or acceptable patient surrogate.

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Xuanwu Hospital
Coordinator of this site? Confirm its status
BeijingChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.